DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir and what is the scope of patent protection?
Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir has six hundred and eight patent family members in fifty-four countries.
Summary for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
| International Patents: | 608 |
| US Patents: | 20 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR |
| DailyMed Link: | DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
Generic Entry Dates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
Generic Entry Dates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
Expired US Patents for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | I402070 | ⤷ Try a Trial | |
| Singapore | 2014011670 | COMBINATION TREATMENT (EG. WITH ABT-072 OR ABT -333) OF DAAS FOR USE IN TREATING HCV | ⤷ Try a Trial |
| Chile | 2014000059 | Compuestos derivados de heterociclos nitrogenados sustituidos; proceso de preparacion; compuesto intermediario; composiciones farmaceuticas; utiles como inhiibidores de la replicacion del hcv para tratar la hepatitis c. (div. sol. 970-13) | ⤷ Try a Trial |
| Chile | 2009001844 | Forma de dosificacion farmaceutica solida que comprende lopinavir y ritonavir formulados en forma de dispersion solida o solucion solida, un polimero soluble en agua y un tensioactivo con valores de hlb de entre 4 y 10, util en el tratamiento de una infeccion por vih (divisional sol. 393-06). | ⤷ Try a Trial |
| Peru | 20061016 | UNA FORMULACION SOLIDA DE DOSIFICACION FARMACEUTICA | ⤷ Try a Trial |
| Slovenia | 2203431 | ⤷ Try a Trial | |
| Netherlands | 300729 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2692346 | C02692346/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66472 22.09.2017 |
| 2368890 | 2015012 | Norway | ⤷ Try a Trial | PRODUCT NAME: OMBITASVIR, ELLER ET; REG. NO/DATE: EU/1/14/982 20150120 |
| 2692346 | PA2017033 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2692346 | C20170036 00243 | Estonia | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017 |
| 2203431 | CA 2015 00014 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
| 2692346 | 712 | Finland | ⤷ Try a Trial | |
| 2340029 | 92667 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
